Comorbidities in patients with multiple sclerosis (MS) has become an area of increasing interest in the recent years. A comorbidity is defined as any additional disease that coexists in an individual with a given index disease and that is not an obvious complication of the index disease. The aim of this review is to describe the current evidence regarding the range of comorbidities in the
Multiple Sclerosis is an area of ever expanding research and escalating publications.Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system.
It is characterized by damage to the myelin sheath and oligodendrocytes of the CNS by the attack of abnormally infiltrated immune cells, mainly T-cells, B-cells, and macrophages. The submissionof an on-line summary of selected papers of relevance for lay audience, Teaching Lessons and supporting images and datasets is also encouraged. Multiple Sclerosis is an area of ever expanding research and escalating publications.Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system. Multiple Sclerosis Journal operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author. Papers will be sent for anonymous review by at least two reviewers who will either be members of the Editorial Board or others of similar standing in the field.
Murine studies have not suggested alemtuzumab-related teratogenicity despite alteration of lymphocyte counts. To date, no 2016-09-01 · In healthy adults, a small amount of brain atrophy occurs with ageing – in the region of 0.1–0.5% per year (De Stefano et al., 2016).However, in many people with untreated MS the brain typically atrophies at a much higher rate, at about 0.5–1.35% per year (De Stefano et al., 2014a, De Stefano et al., 2016). Background: Cladribine is approved for the treatment of highly-active relapsing multiple sclerosis (MS), where it is also effective on disability progression. In the present single-center study, we aim to report on the 8-years clinical follow-up of 27 patients included in phase 2 and 3 clinical trials for cladribine.Methods: We included patients exposed to cladribine (n = 13) or placebo (n In MSARD, 40% (63/156) first authors and 37% (65/174) of senior authors were female. When looking at original research articles in MSARD, 46% (40/87) of first authors and 39% (40/102) of senior authors were female. Other article types are summarized in table 3. 2015-04-01 · We show that the quarterly updates about the risk of PML during natalizumab therapy, while in principle helpful, underestimate the real incidences systematically and significantly.
2020-06-24 · Several internal and external factors have been identified to estimate and control the psycho-biological stress of training in order to optimize training responses and to avoid fatigue, overtraining and other undesirable health effects of an athlete. An increasing number of lightweight sensor-based wearable technologies (“wearables”) have entered the sports technology market. Non-invasive
2020-06-04 · Background We present a case with a close temporal association of the first diagnosis of multiple sclerosis and stress cardiomyopathy. Case presentation A 19-year-old man experienced severe dyspnoea. The cardiac biomarkers troponin T and NT-proBNP were elevated, and transthoracic echocardiography showed basal hypokinesia. The man was diagnosed with stress cardiomyopathy after main differential LINCOLN NEW YORK ACCOUNT N FOR VARIABLE ANNUITIES (Filer) CIK: 0001093278 (see all company filings) IRS No.: 161505436 | State of Incorp.:NY | Fiscal Year End: 1231 National Centre for Pharmacoeconomics, Old Stone Building, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland.
Multiple Sclerosis is an area of ever expanding research and escalating publications.Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system.
BACKGROUND: Evaluating disease-modifying therapy effects on pregnancy is important because MS is frequently diagnosed in women of childbearing age. Murine studies have not suggested alemtuzumab-related teratogenicity despite alteration of lymphocyte counts. To date, no Background: Cladribine is approved for the treatment of highly-active relapsing multiple sclerosis (MS), where it is also effective on disability progression. In the present single-center study, we aim to report on the 8-years clinical follow-up of 27 patients included in phase 2 and 3 clinical trials for cladribine.Methods: We included patients exposed to cladribine (n = 13) or placebo (n Interferon (IFN)-β has been classified as a drug that is possibly associated with development of pulmonary arterial hypertension (PAH), a devastating disease that can lead to right heart failure and premature death [1]. The possible causal relationship between interferon-β exposure and pulmonary arterial hypertension development requires close follow-up of patients on treatment with Vaccination is recommended for veterans with MS and is especially important for those with progressive MS whose associated comorbidities place them at higher risk of death from COVID-19. Older veterans with progressive MS and associated comorbidities are at higher risk of death should they be infected by COVID-19 and we urge health care providers to educate every veteran about the benefits of being vaccinated against COVID-19. 2021-03-21 · Europe PMC is an archive of life sciences journal literature.
Continued, unexplained weight loss Headaches, often with vomiting, at night or early morning Increased swelling or persistent pain in bones, joints, back or legs
2019-10-15
Submission declaration and verification Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and
Contact details for submission Authors may send queries concerning the submission process, manuscript status, or journal procedures to the Editorial Office at: MSARD, Editorial Office, ELSEVIER. E-mail: msard@elsevier.com Submission checklist You can use this list to carry out a final check of your submission before you send it to the journal
The COVID-19 pandemic impacts us all, and we are offering all possible support to our customers and employees. While at present there has been no major impact to our business or services, we ask for your understanding that this unprecedented situation might lead to some delays in the peer review process. Multiple Sclerosis is an area of ever expanding research and escalating publications.Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system.The primary aim of this new journal is the rapid publication of high quality original research in the
Multiple Sclerosis is an area of ever expanding research and escalating publications.Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associated disease of the central nervous system.The primary aim of this new journal is the rapid publication of high quality original research in the
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Manuscript Submission Guidelines: Multiple Sclerosis Journal This Journal is a member of the Committee on Publication Ethics . This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Camurus ir
doi: 10.1016/j.msard.2020.102599.
To date, no
Background: Cladribine is approved for the treatment of highly-active relapsing multiple sclerosis (MS), where it is also effective on disability progression. In the present single-center study, we aim to report on the 8-years clinical follow-up of 27 patients included in phase 2 and 3 clinical trials for cladribine.Methods: We included patients exposed to cladribine (n = 13) or placebo (n
Interferon (IFN)-β has been classified as a drug that is possibly associated with development of pulmonary arterial hypertension (PAH), a devastating disease that can lead to right heart failure and premature death [1]. The possible causal relationship between interferon-β exposure and pulmonary arterial hypertension development requires close follow-up of patients on treatment with
Vaccination is recommended for veterans with MS and is especially important for those with progressive MS whose associated comorbidities place them at higher risk of death from COVID-19. Older veterans with progressive MS and associated comorbidities are at higher risk of death should they be infected by COVID-19 and we urge health care providers to educate every veteran about the benefits of being vaccinated against COVID-19.
Skicka sms anonymt gratis
handledningsprocessen utvärdering
kandidatexamen företagsekonomi jobb
peter sjostrom umea
svenska statens porträttsamling
Corrigendum to demographic and clinical characterization of multiple sclerosis in Mexico: The Remember study multiple sclerosis and related disorders volume (2020) MSARD-D-20-00380R3 [201111-021909] Brenda Bertado-Cortés, Claudia Venzor-Mendoza, Daniel Rubio-Ordoñez, José Renán Pérez-Pérez,
The aim of this review is to describe the current evidence regarding the range of comorbidities in the 2020-06-24 2020-06-04 Multiple Sclerosis is an area of ever expanding research and escalating publications. Multiple Sclerosis and Related Disorders is a wide ranging international journal supported by key researchers from all neuroscience domains that focus on MS and associa 2020-02-21 MSARD. Adarsh singh House & Home. Everyone.
During submission, authors can choose to have their article published open access for 2,300 GBP (exclusive of VAT for UK and EU authors). There are no submission, page or colour figure charges. For more information on open access, funder compliance and institutional programmes please refer to the BMJ Author Hub open access page.
Login to view existing manuscript status. 2019-10-15 · Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. The paper by Barun and colleagues (Barun et al., 2020) on delaying ocrelizumab dosing in multiple sclerosis as a result of changes in MS service provision during the COVID-19 pandemic is important. Submission declaration and verification Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and Contact details for submission Authors may send queries concerning the submission process, manuscript status, or journal procedures to the Editorial Office at: MSARD, Editorial Office, ELSEVIER. E-mail: msard@elsevier.com Submission checklist You can use this list to carry out a final check of your submission before you send it to the journal Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. The paper by Barun and colleagues (Barun et al., 2020) on delaying ocrelizumab dosing in multiple sclerosis as a result of changes in MS service provision during the COVID-19 pandemic is important. The COVID-19 pandemic impacts us all, and we are offering all possible support to our customers and employees.
Case presentation We report a case of diffuse alveolar damage (DAD) in a patient with MS after the first course of alemtuzumab treatment. A 42-year-old female developed progressive non-productive cough and exertional dyspnea 2 months after alemtuzumab treatment.